A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants.

In 30 seconds

This Phase 1 open-label trial evaluated the pharmacokinetics, pharmacodynamics, and safety of zerlasiran in 18 Japanese adults with elevated lipoprotein(a). The study found a maximum median reduction in lipoprotein(a) of -97.8% in the 300 mg cohort between days 30 and 60, with sustained effects observed at 150 days.

Key findings

• Maximum median reduction in lipoprotein(a) was -72.8%, -88.8%, and -97.8% for 30 mg, 100 mg, and 300 mg doses, respectively.
• Plasma concentrations of zerlasiran declined to undetectable levels by 36 hours post-dose.
• All adverse events reported were mild and self-limiting.

Why it matters

Understanding the pharmacokinetics and safety profile of zerlasiran in a specific population is crucial for assessing its potential as a treatment for elevated lipoprotein(a), a significant cardiovascular risk factor.